IRIS
GATTO, FEDERICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.466
AS - Asia 1.265
NA - Nord America 1.229
SA - Sud America 106
AF - Africa 17
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 11.086
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 8.245
US - Stati Uniti d'America 1.143
SG - Singapore 468
CN - Cina 291
VN - Vietnam 212
BD - Bangladesh 179
FR - Francia 77
BR - Brasile 75
FI - Finlandia 45
HK - Hong Kong 43
CA - Canada 35
DE - Germania 26
GB - Regno Unito 21
IQ - Iraq 14
MX - Messico 14
AR - Argentina 13
IE - Irlanda 10
JP - Giappone 10
JM - Giamaica 9
ID - Indonesia 8
PH - Filippine 8
CR - Costa Rica 7
CH - Svizzera 6
IN - India 6
NL - Olanda 6
ZA - Sudafrica 6
RU - Federazione Russa 5
VE - Venezuela 5
CO - Colombia 4
ES - Italia 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
EC - Ecuador 3
GT - Guatemala 3
HN - Honduras 3
MA - Marocco 3
SV - El Salvador 3
TH - Thailandia 3
TR - Turchia 3
UA - Ucraina 3
AZ - Azerbaigian 2
BE - Belgio 2
BY - Bielorussia 2
CW - ???statistics.table.value.countryCode.CW??? 2
DZ - Algeria 2
KZ - Kazakistan 2
NI - Nicaragua 2
NP - Nepal 2
PR - Porto Rico 2
PT - Portogallo 2
SE - Svezia 2
TT - Trinidad e Tobago 2
AL - Albania 1
AT - Austria 1
AU - Australia 1
BB - Barbados 1
BG - Bulgaria 1
BO - Bolivia 1
BZ - Belize 1
DJ - Gibuti 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GA - Gabon 1
HR - Croazia 1
IL - Israele 1
JO - Giordania 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
LT - Lituania 1
MM - Myanmar 1
MQ - Martinica 1
MU - Mauritius 1
MY - Malesia 1
NE - Niger 1
NG - Nigeria 1
OM - Oman 1
PE - Perù 1
PK - Pakistan 1
PS - Palestinian Territory 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
UZ - Uzbekistan 1
VI - Stati Uniti Isole Vergini 1
Totale 11.086
Salva come PNG Salva come JPEG
Città #
Genova 3.923
Genoa 2.757
Vado Ligure 821
Rapallo 520
San Jose 320
Singapore 223
Ashburn 126
Council Bluffs 69
Lauterbourg 68
Ho Chi Minh City 57
Hanoi 50
Beijing 45
New York 45
Hong Kong 39
Helsinki 33
Santa Clara 30
Boardman 24
Rome 21
Los Angeles 18
Frankfurt am Main 17
Milan 17
Haiphong 14
Bologna 13
Chicago 12
Hamilton 12
Lappeenranta 12
Newark 11
St Louis 11
Bordighera 10
Orem 10
Tokyo 10
Turin 10
Atlanta 9
Brooklyn 9
Naples 9
Buffalo 8
Da Nang 8
Dublin 8
London 8
Montreal 8
Toronto 8
Kingston 7
Mexico City 7
Philadelphia 7
Biên Hòa 6
San Francisco 6
São Paulo 6
Can Tho 5
Carrabelle 5
Dallas 5
Hayward 5
Johannesburg 5
Memphis 5
Odessa 5
San José 5
Zurich 5
Baghdad 4
Birmingham 4
Bristol 4
City of London 4
Cleveland 4
Corona 4
Denver 4
Des Moines 4
Fayetteville 4
Florence 4
Fort Lauderdale 4
Hải Dương 4
Modena 4
Ninh Bình 4
Piscataway 4
Reggio Emilia 4
Shanghai 4
Strafford 4
Thái Nguyên 4
Tianjin 4
Albignasego 3
Catania 3
Charlotte 3
Hamburg 3
Miami 3
Palermo 3
Porto Alegre 3
Rhodesdale 3
San Juan 3
San Salvador 3
Schiffdorf 3
Todi 3
Acerra 2
Baku 2
Bangkok 2
Bogotá 2
Brescia 2
Brussels 2
Buenos Aires 2
Cardiff 2
Carmichael 2
Carrollton 2
Cary 2
Changsha 2
Totale 9.647
Salva come PNG Salva come JPEG
Nome #
Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients 242
Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy? 225
Conventional and nuclear medicine imaging in Ectopic Cushing's syndrome: A systematic review 220
SOMATOSTATIN AND DOPAMINE RECEPTOR INTERACTION IN PROSTATE AND LUNG CANCER CELL LINES 213
Diabetes secondary to neuroendocrine gastroenteropancreatic tumors 211
Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells 207
The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology 194
Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas 189
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms 187
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogs and dopastatins 186
Hormone receptors analysis in idiopathic progressive subglottic stenosis 186
Emerging targets in pituitary adenomas: role of the CXCL12/CXCR4-R7 system 185
Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth. 182
Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors 180
Case report: Twice-daily tolvaptan dosing regimen in a challenging case of hyponatremia due to SIAD 176
Aggressive and malignant prolactinomas 169
Somatostatin receptor scintigraphy in thoracic diseases 162
Octreotide and pasireotide combination treatment in somatotroph tumor cells: Predominant role of sst2 in mediating ligand effects 162
Somatostatin receptor ligands in the treatment of acromegaly 160
Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly 158
Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly 158
Does pasireotide directly modulate skeletal muscle metabolism? 154
Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature 153
Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database 153
Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center 152
Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly 152
Emerging drugs for the treatment of acromegaly 150
Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management 149
Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells 149
P68 Insulin-like growth factor (IGF) binding protein-3 inhibits IGF-II-stimulated IRS-1/PI-3-kinase activity and cell growth in human non-small cell lung cancer (NSCLC) cell lines 148
OR2,6 Interrelationship between somatostatin/dopamine pathways and growth factors in non-small lung cancer cells 147
Diagnosis and Treatment of Parasellar Lesions 145
P87 Effect of exenatide, sitagliptin and vildagliptin on IGF-I in diabetic patients 141
Regulation Of Prostate Cancer Cell Proliferation By Somatostatin Receptor Activation 140
In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5 140
Abstracts of the 6th Annual ENETS Conference, Granada, Spain, March 5–7, 2009 136
The role of somatostatin and dopamine D2 receptors in endocrine tumors 136
In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas 134
Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives 134
Hyperthyroidism in non-seminomatous testicular germ cell tumors: two case reports and literature review 133
Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment 132
Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: implications for the in vivo visualization during somatostatin receptor scintigraphy. 130
Pre-surgical treatment with somatostatin analogues in patients with acromegaly: The case for 130
Novel chimeric somatostatin analogs: facts and perspectives 129
Temporal and masseter muscle evaluation by MRI provides information on muscle mass and quality in acromegaly patients 127
Body Composition and Bone Status in Relation to Microvascular Damage in Systemic Sclerosis Patients 127
Modulatory activity of testosterone on growth pattern and IGF-1 levels in vanishing testis syndrome: a case report during 15 years of follow-up 125
PD-L1 expression, BRAF and TERT mutation in a cohort of aggressive thyroid cancers: case series from a single-centre experience 124
Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective 123
Extraintestinal precoccygeal tumour with endocrine features and its relationship with Currarino syndrome. 122
Digital quantification of somatostatin receptor subtypes 2 and 5 in growth hormone–secreting pituitary tumors 117
Baseline testosterone levels as a predictor of hypogonadism resolution in male patients with isolated hyperprolactinemia 112
An unusual cause of adrenal insufficiency with elevation of 17-hydroxyprogesterone: case report 112
null 110
null 110
null 109
Differential Impact of Medical Therapies for Acromegaly on Glucose Metabolism 108
Ultra-short antibiotic prophylaxis guided by preoperative microbiological nasal swabs in endoscopic endonasal skull base surgery 107
Novel Molecular Mechanisms of Resistance to Somatostatin Analog Treatment in Pituitary Adenomas 105
null 104
The effect of sodium restriction on iodine prophylaxis: a review 104
GH Replacement in the Elderly: Is It Worth It? 104
Challenging diagnosis of resistance to thyroid hormone in a patient with COVID-19, pituitary microadenoma and unusual response to octreotide long-acting release test 98
Sodium Intake and Target Organ Damage in Hypertension-An Update about the Role of a Real Villain 88
Acromegaly Management in a Tertiary Referral Center After 1 Year of the Coronavirus 2019 Pandemic: A Double Challenge 84
Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients 82
Somatostatin receptors and the associated intracellular machinery: the two sides of the coin 81
Dissecting the in vitro efficacy of octreotide and cabergoline in GH- and GH/PRL-secreting pituitary tumors 81
Trabecular Bone Score as a Reliable Measure of Lumbar Spine Bone Microarchitecture in Acromegalic Patients 78
Cemiplimab and diabetic ketoacidosis: a case report of a rare endocrinopathy associated with immune checkpoint inhibitors 77
Corrigendum to "Regulation of prostate cancer cell proliferation by somatostatin receptor activation" [Mol. Cell. Endocrinol. 315 (1-2) (2010) 254-262] 75
Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study 75
Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs 74
Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression 73
Left ventricular mass reduction by a low-sodium diet in treated hypertensive patients 68
Cushing's syndrome 64
β-arrestin expression in corticotroph tumor cells is modulated by glucocorticoids 64
Off-label pasireotide treatment in one insulinoma patient with an atypical presentation and intolerant to diazoxide 62
Skeletal Muscle Evaluation in Patients With Acromegaly 62
Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length 61
null 61
Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study. 57
Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies. 53
The paradoxical GH response at OGTT does not predict Pasireotide efficacy but matters for glucose metabolism 50
Editorial: Resistance to Medical Therapy in Pituitary Tumors 45
Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1 39
Octreotide-resistant acromegaly: Challenges and solutions 38
La composizione dei macronutrienti nella dieta influenza l’asse somatotropo: un potenziale trattamento per l’acromegalia? 35
Impact of Nutrition on Somatotroph Axis: A Potential Role in Acromegaly and Its Cardiovascular Risk? 34
Routine Evaluation of Somatostatin Receptor Type 2 in Patients With Acromegaly: Do We Still Need More Evidence? 32
Current clinical practice for thromboprophylaxis management in patients with Cushing's syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN) 32
Gender differences in the glycometabolic and cardiovascular features of acromegaly 31
Who and how to screen for Cushing’s syndrome: the position statement of the Italian Society of Endocrinology 31
Venous thromboembolism in Cushing syndrome: results from an EuRRECa and Endo-ERN survey 29
Metabolic syndrome in cushing’s syndrome patients: Does gender matter? 29
null 28
European survey on metabolic and cardiovascular risk in Cushing syndrome 26
Somatostatin receptor pathophysiology in the neuroendocrine system 24
Global epidemiology of acromegaly: a systematic review and meta-analysis 24
Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant 23
Totale 11.337
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.433
article - articoli 36.550
book - libri 297
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 586
Totale 74.866
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022709 16 14 80 95 26 56 26 166 51 61 26 92
2022/2023641 56 62 5 47 68 105 18 41 118 11 98 12
2023/2024502 25 54 10 61 29 87 42 24 27 39 37 67
2024/20251.994 71 131 59 146 263 219 191 316 73 84 201 240
2025/20263.850 405 86 348 337 414 289 488 156 303 373 262 389
2026/2027343 343 0 0 0 0 0 0 0 0 0 0 0
Totale 11.393